

Disclaimer: The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.

More Details on www.microport.com.cn

Email ir@microport.com

Tel (021) 38954600

Fax (021) 50801305

MicroPort Orthopedic Products Approved for Marketing

MicroPort Orthopedic Products have recently achieved approval by the Shanghai Food and Drug Administration. MicroPort can now commence domestic marketing activities for our new Orthopedic products, including Spine Posterior Fixation System, Anterior Cervical Plate System, Cervical Fusion Device, and Thoracic & Lumbar Fusion Device.

This represents something of a milestone for MicroPort, being the first time our Orthopedic products have gained SFDA approval, and it creates significant opportunity for MicroPort to expand into this growing segment of the Chinese domestic market.

The 30-Day Follow-Up Result of FIRE2-DIABETES

The 22nd GW-ICC was held at China National Convention Center in Beijing from October 10-16. During the congress, MicroPort organized a satellite meeting on the theme of Firebird2 drug-eluting stents in the treatment of complex lesions in diabetic patients. MicroPort also published the 30-day follow-up result of the FIRE2-DIABETES clinical studies. According to the result of the clinical studies, the success rate was 100% with 100% lesion achievement ratio, 0.3% 30-day cumulative cardiac

death rate. The incidence of TVR, MACE and Late Thrombosis was 0.3%, 0.8% and 0.4% respectively. Meanwhile, the 6-month and 1-year follow-up of the clinical studies are also in process.

FIRE2-DIABETES is the first international multi-center prospective clinical registry research in China, using Cocr drug-eluting stents to treat complex coronary lesion in diabetic patients. All of the implanted stents were Firebird2 Cocr alloyed sirolimus-eluting stents. The findings of the research will provide scientific evidence in the treatment of complex coronary lesion in diabetic patients and further prove the efficacy and safety of Firebird2.

The Clinical Result of Micro Pulse Infusion Pumps Published

The clinical result of the Micro Pulse Infusion Pump has been published in the <Chinese Journal of Endocrinology and Metabolism>(2011-8). The clinical results, also proved the efficacy of the new product. Developed jointly by Shanghai MicroPort Lifesciences Co., Ltd. and Shanghai Ruijin Hospital, the pulsatile infusion of Gonadotropin-Releasing Hormone (GnRH) is for the treatment of idiopathic hypogonadotropic hypogonadism (IHH). Research in China and this is the first micro pulse infusion system which can be used for the effective treatment of -sized device with

microcomputer-control micro-precision motor for accurate and safe hypodermatoclysis. It is also featured as personalized settings, simple operation and easy to carry.

Share Repurchase

From September 20th 2011 to October 18th 2011, MicroPort Scientific Corporation (00853) has repurchased 18,500,000 shares in total.

Dr. Zhaohua Chang accepts the Chairmanship of Shanghai Pudong Federation of Industry and Commerce

Representative Convention of the Shanghai Pudong Federation of Industry and Commerce, was held in China Executive Leadership Academy Pudong (Shanghai). Those attending the convention included: Xu Lin, the Standing Committee of Shanghai Municipal Party Committee, Secretary of the Pudong New Area District; Wang Xinkui, Vice Chairman of the Shanghai CPPCC and Chairman of the Shanghai Federation of Industry and Commerce; and 450 representatives from business and industry sectors. Dr. Zhaohua Chang, Executive Director and Chairman of MicroPort Medical (Shanghai) Co., Ltd. was elected President of the 5th Executive Council and Chairman of the Shanghai Pudong Federation of Industry and Commerce.

MicroPort Distributor Meeting “From Zero to Hero” Held in Beijing

In order to meet the high demand of coronary accessories in the domestic market, Goodman had signed an agreement to authorize MicroPort as its general distributor in China. On October 14, 2011,

of MicroPort Medical (Shanghai) Co., Ltd. was successfully held in Beijing. The meeting, which was organized by the Surgery Accessories Division of MicroPort, was chaired by Ms. Yi Kejing. Attending were, Mr. Philip Li Wang, COO of MicroPort; Mr. Peng Bo, CMO of MicroPort; Ms. Ma Hongyan, Marketing and Sales Manager of the Surgery Accessories Division of MicroPort. Mr. Lv Linhai, Country President of Goodman China; Mr. Yamamoto, Director of the Overseas Planning Department of Goodman, and over 50 representatives from distributor companies partnered with MicroPort, also joined the meeting. The meeting focused on Proxy and aimed at

further strengthening exchanges, cooperation, and seeking common development.

